Once again, MRI has outrun other modalities as a supplemental tool for screening high-risk women.
A large prospective screening trial from the University of Pennsylvania compared screen-film mammography, digital mammography, whole-breast ultrasound, and contrast-enhanced MRI in a population of 569 asymptomatic women. In this single-center trial, funded by the National Cancer Institute, the definition of high risk included women with a 25% lifetime risk based on genetic testing or Gail or Claus models and those with a history of cancer in the contralateral breast.
Of 95 lesions recommended for biopsy, 11 were malignant (11.6%). Seven of the 11 cancers were seen on only one modality: one with digital mammography and six with MRI alone. No cases were seen on either screen-film mammography or ultrasound alone.
"In our study, MRI detected the highest percentage of clinically occult breast cancers in a high-risk population, more than digital mammography, ultrasound, and screen-film mammography," said RSNA meeting presenter Dr. Lily Kernagis, a fellow in women's imaging at Penn.
Follow-up was carried out for one to three years and revealed no new breast cancer diagnoses. Based on the results and follow-up, multimodality screening had a negative predictive value of 100%, sensitivity of 100%, and specificity of 84.9%.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.